# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Financial Framework Novavax is updating its Full Year 2024 Financial Guidance and expects to achieve the following objectives:...
Novavax (NASDAQ:NVAX) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(1.06) by 0....
Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined c...
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.
-Reuters Citing Spokesperson
https://ir.novavax.com/press-releases/Novavax-to-Supply-Updated-COVID-19-Vaccine-to-Private-Healthcare-Providers-in-the-United-...
In a new regulatory filing, Shah Capital, which owns 9.3 million shares of Novavax representing a 6.66% stake in the company, e...